165 related articles for article (PubMed ID: 18045953)
1. Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells.
De los Santos M; Martínez-Iglesias O; Aranda A
Endocr Relat Cancer; 2007 Dec; 14(4):1021-8. PubMed ID: 18045953
[TBL] [Abstract][Full Text] [Related]
2. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer.
Saji S; Kawakami M; Hayashi S; Yoshida N; Hirose M; Horiguchi S; Itoh A; Funata N; Schreiber SL; Yoshida M; Toi M
Oncogene; 2005 Jun; 24(28):4531-9. PubMed ID: 15806142
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells.
Davis T; Kennedy C; Chiew YE; Clarke CL; deFazio A
Clin Cancer Res; 2000 Nov; 6(11):4334-42. PubMed ID: 11106251
[TBL] [Abstract][Full Text] [Related]
4. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Munster PN; Troso-Sandoval T; Rosen N; Rifkind R; Marks PA; Richon VM
Cancer Res; 2001 Dec; 61(23):8492-7. PubMed ID: 11731433
[TBL] [Abstract][Full Text] [Related]
5. [Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells].
Meng QW; Zhao CH; Xi YH; Cai L; Sun LC; Sui GJ
Ai Zheng; 2006 Aug; 25(8):967-73. PubMed ID: 16965676
[TBL] [Abstract][Full Text] [Related]
6. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells.
Yang X; Phillips DL; Ferguson AT; Nelson WG; Herman JG; Davidson NE
Cancer Res; 2001 Oct; 61(19):7025-9. PubMed ID: 11585728
[TBL] [Abstract][Full Text] [Related]
8. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
Pink JJ; Jordan VC
Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibition and estrogen signalling in human breast cancer cells.
Margueron R; Duong V; Castet A; Cavaillès V
Biochem Pharmacol; 2004 Sep; 68(6):1239-46. PubMed ID: 15313422
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells.
Hodges-Gallagher L; Valentine CD; Bader SE; Kushner PJ
Breast Cancer Res Treat; 2007 Nov; 105(3):297-309. PubMed ID: 17186358
[TBL] [Abstract][Full Text] [Related]
11. Opposite effects of histone deacetylase inhibitors on glucocorticoid and estrogen signaling in human endometrial Ishikawa cells.
Rocha W; Sanchez R; Deschênes J; Auger A; Hébert E; White JH; Mader S
Mol Pharmacol; 2005 Dec; 68(6):1852-62. PubMed ID: 16186250
[TBL] [Abstract][Full Text] [Related]
12. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling.
Yi X; Wei W; Wang SY; Du ZY; Xu YJ; Yu XD
Biochem Pharmacol; 2008 May; 75(9):1697-705. PubMed ID: 18342836
[TBL] [Abstract][Full Text] [Related]
14. Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90.
Fiskus W; Ren Y; Mohapatra A; Bali P; Mandawat A; Rao R; Herger B; Yang Y; Atadja P; Wu J; Bhalla K
Clin Cancer Res; 2007 Aug; 13(16):4882-90. PubMed ID: 17699868
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.
Heider U; Kaiser M; Sterz J; Zavrski I; Jakob C; Fleissner C; Eucker J; Possinger K; Sezer O
Eur J Haematol; 2006 Jan; 76(1):42-50. PubMed ID: 16343270
[TBL] [Abstract][Full Text] [Related]
16. Estradiol-induced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway.
Sengupta K; Banerjee S; Saxena N; Banerjee SK
Int J Oncol; 2003 Mar; 22(3):609-14. PubMed ID: 12579315
[TBL] [Abstract][Full Text] [Related]
17. Effects of histone deacetylase inhibitors on estradiol-induced proliferation and hyperplasia formation in the mouse uterus.
Gunin AG; Kapitova IN; Suslonova NV
J Endocrinol; 2005 Jun; 185(3):539-49. PubMed ID: 15930180
[TBL] [Abstract][Full Text] [Related]
18. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
19. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
Huang L; Sowa Y; Sakai T; Pardee AB
Oncogene; 2000 Nov; 19(50):5712-9. PubMed ID: 11126357
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome proliferator-activated receptor alpha expression is regulated by estrogen receptor alpha and modulates the response of MCF-7 cells to sodium butyrate.
Faddy HM; Robinson JA; Lee WJ; Holman NA; Monteith GR; Roberts-Thomson SJ
Int J Biochem Cell Biol; 2006 Feb; 38(2):255-66. PubMed ID: 16226051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]